116 related articles for article (PubMed ID: 38711384)
1. Incidence and survival of primary metastatic breast cancer in Denmark; implication of breast cancer screening, classification, and staging practice.
Berg T; Jensen MB; Rossing M; Axelsen CT; Kümler I; Søndergaard L; Vogsen M; Knoop AS; Ejlertsen B
Acta Oncol; 2024 May; 63():277-287. PubMed ID: 38711384
[TBL] [Abstract][Full Text] [Related]
2.
Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological differences between breast cancer in patients with primary metastatic disease and those without: a multicentre study.
Barinoff J; Hils R; Bender A; Groß J; Kurz C; Tauchert S; Mann E; Schwidde I; Ipsen B; Sawitzki K; Heitz F; Harter P; Traut A; du Bois A
Eur J Cancer; 2013 Jan; 49(2):305-11. PubMed ID: 22940292
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016.
Thomas A; Rhoads A; Suhl J; Conway KM; Hundley WG; McNally LR; Oleson J; Melin SA; Lynch CF; Romitti PA
Clin Breast Cancer; 2020 Aug; 20(4):e410-e422. PubMed ID: 32278642
[TBL] [Abstract][Full Text] [Related]
5. Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer.
Bychkovsky BL; Guo H; Sutton J; Spring L; Faig J; Dagogo-Jack I; Battelli C; Houlihan MJ; Yeh TC; Come SE; Lin NU
Oncologist; 2016 Dec; 21(12):1495-1501. PubMed ID: 27551013
[TBL] [Abstract][Full Text] [Related]
6. Overuse of Preoperative Staging of Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer.
Srour MK; Lee M; Walcott-Sapp S; Luu M; Chung A; Giuliano AE; Amersi F
Ann Surg Oncol; 2019 Oct; 26(10):3289-3294. PubMed ID: 31342365
[TBL] [Abstract][Full Text] [Related]
7. Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology.
Uyeturk U; Oksuzoglu B; Akman T; Turker I; Sener N; Tastekin D; Bal O; Berk V; Arslan UY; Urakci Z; Bilir C; Yilmaz U; Yazilitas D; Ulas A; Sonmez OU; Budakoglu B; Cihan S; Uysal M
Med Oncol; 2014 Apr; 31(4):929. PubMed ID: 24659267
[TBL] [Abstract][Full Text] [Related]
8.
Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
[TBL] [Abstract][Full Text] [Related]
9. ER
Arciero CA; Guo Y; Jiang R; Behera M; O'Regan R; Peng L; Li X
Clin Breast Cancer; 2019 Aug; 19(4):236-245. PubMed ID: 30846407
[TBL] [Abstract][Full Text] [Related]
10. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
11. Effect of adjuvant chemotherapy in patients with ER + /HER2- breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status.
Tanaka N; Hirano A; Hattori A; Ogura K; Kamimura M; Inoue H; Yukawa H; Sakaguchi S; Matsuoka A; Kodera A; Shimizu T
Breast Cancer; 2021 Jan; 28(1):40-47. PubMed ID: 32592141
[TBL] [Abstract][Full Text] [Related]
12. Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer.
Ogiya R; Sagara Y; Niikura N; Freedman RA
Clin Breast Cancer; 2019 Jun; 19(3):200-207.e1. PubMed ID: 30795886
[TBL] [Abstract][Full Text] [Related]
13. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
14. Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma: a population-based study from China.
Cao AY; He M; Liu ZB; Di GH; Wu J; Lu JS; Liu GY; Shen ZZ; Shao ZM
Ann Surg Oncol; 2012 Sep; 19(9):3019-27. PubMed ID: 22451233
[TBL] [Abstract][Full Text] [Related]
15. [Survival of patients with metastatic breast cancer according to pathological types of tumors].
Sánchez R C; Acevedo C F; Petric G M; Galindo A H; Domínguez C F; León R A; Razmilic V D; Ceballos C; Espinoza F; Navarro O ME; Oddó B D; Camus A M
Rev Med Chil; 2014 Apr; 142(4):428-35. PubMed ID: 25117032
[TBL] [Abstract][Full Text] [Related]
16. Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients.
Yang YF; Liao YY; Yang M; Peng NF; Xie SR; Xie YF
Med Oncol; 2014 Oct; 31(10):214. PubMed ID: 25216864
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
[TBL] [Abstract][Full Text] [Related]
18. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
Bauer K; Parise C; Caggiano V
BMC Cancer; 2010 May; 10():228. PubMed ID: 20492696
[TBL] [Abstract][Full Text] [Related]
19. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
[TBL] [Abstract][Full Text] [Related]
20. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
